Ovarian Metastasis Is Associated with Retroperitoneal Lymph Node Relapses in Women Treated for Colorectal Peritoneal Carcinomatosis

Ovarian Metastasis Is Associated with Retroperitoneal Lymph Node Relapses in Women Treated for Colorectal Peritoneal Carcinomatosis

Abstract

Purpose  

To analyze the patterns of recurrence and the prognostic impact of ovarian metastases (OM) in a population of women with colorectal
peritoneal carcinomatosis (CRPC) treated with curative intent.

Methods  

Data from all consecutive women with CRPC who underwent curatively intended complete cytoreductive surgery (CRS) plus intraperitoneal
chemotherapy at our institution were retrieved from a prospective database. A bilateral oophorectomy or a complementary unilateral
oophorectomy was systematically performed during CRS.

Results  

From 1994 to 2009, among 105 women who underwent CRS plus intraperitoneal chemotherapy for CRPC, 62 (60 %) had OM. Women with
and without OM had comparable peritoneal cancer index (PCI) scores (10 vs. 12, respectively, p = 0.09). After a median follow-up of 60 (range 5–145) months, median overall survival of women with OM did not differ statistically
from that of women without OM (respectively, 36 and 40 months; p = 0.75). Relapses occurred in 82 % of the patients, distributed similarly between the two groups except for retroperitoneal
lymph node recurrence, which occurred in 19 patients (18 %), including 18 with OM. The only predictive factor for a retroperitoneal
relapse was a history of OM (p = 0.0012).

Conclusions  

Retroperitoneal lymph node recurrence seems to be linked to OM originating from colorectal cancer and could worsen the prognosis.
A systematic lymphadenectomy could be evaluated in women with isolated OM or very limited peritoneal carcinomatosis to analyze
the incidence of invaded lymph nodes and study its potential benefit on survival.

• Content Type Journal Article
• Category Colorectal Cancer
• Pages 1-6
• DOI 10.1245/s10434-012-2623-9
• Authors
  
  
  • Clarisse Eveno, Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
  • Diane Goéré, Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
  • Peggy Dartigues, Department of Biopathology, Institut Gustave Roussy, Villejuif Cedex, France
  • Charles Honoré, Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
  • Frédéric Dumont, Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
  • Dimitri Tzanis, Department of Surgical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
  • Léonor Benhaim, Department of Surgical Oncolo...

Sent from my iPhone